{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Quindos G"],"funding":["Eusko Jaurlaritza"],"pagination":["906563"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9149255"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12"],"pubmed_abstract":["<h4>Background</h4>Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.<h4>Objective</h4>The aim of this study was to assess the <i>in vitro</i> activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of <i>Candida</i>.<h4>Methods</h4>Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 <i>Candida albicans</i>, 108 <i>Candida parapsilosis</i>, 60 <i>Candida glabrata</i>, 40 <i>Candida tropicalis</i>, 29 <i>Candida krusei</i>, 20 <i>Candida orthopsilosis</i>, 6 <i>Candida guilliermondii</i>, 2 <i>Candida famata</i>, 2 <i>Can"],"journal":["Frontiers in cellular and infection microbiology"],"pubmed_title":["<i>In Vitro</i> Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of <i>Candida</i>: A European Study."],"pmcid":["PMC9149255"],"funding_grant_id":["Consejería de Educación, Universidades e Investigación del Gobierno Vasco (GIC15 IT-990-16)"],"pubmed_authors":["Guridi A","Ezpeleta G","Guarro J","Miranda-Cadena K","Marcos-Arias C","Quindos G","Sanchez-Reus F","Hamprecht A","Romeo O","Pais C","Rodriguez-Iglesias MA","Eraso E","Linares-Sicilia MJ","Machuca-Barcena J","Rezusta A","Borroto-Esoda K","San-Millan R","Lopez-Soria L","Angulo D","Ruiz-Gaitan A","Castro-Mendez C","Vidal-Garcia M","Lorenzo D","Pereira J","Tortorano AM","Jauregizar N","Capilla J","Montesinos I","Martin-Mazuelos E","Peman J","Prigitano A","Fernandez-Rivero M","Canton E"],"additional_accession":[]},"is_claimable":false,"name":"<i>In Vitro</i> Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of <i>Candida</i>: A European Study.","description":"<h4>Background</h4>Ibrexafungerp (SCY-078) is the newest oral and intravenous antifungal drug with broad activity, currently undergoing clinical trials for invasive candidiasis.<h4>Objective</h4>The aim of this study was to assess the <i>in vitro</i> activity of ibrexafungerp and comparators against a collection of 434 European blood isolates of <i>Candida</i>.<h4>Methods</h4>Ibrexafungerp, caspofungin, fluconazole, and micafungin minimum inhibitory concentrations (MICs) were collected from 12 European laboratories for 434 blood isolates, including 163 <i>Candida albicans</i>, 108 <i>Candida parapsilosis</i>, 60 <i>Candida glabrata</i>, 40 <i>Candida tropicalis</i>, 29 <i>Candida krusei</i>, 20 <i>Candida orthopsilosis</i>, 6 <i>Candida guilliermondii</i>, 2 <i>Candida famata</i>, 2 <i>Can","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022","modification":"2025-04-26T07:31:44.088Z","creation":"2025-04-06T12:17:23.907Z"},"accession":"S-EPMC9149255","cross_references":{"pubmed":["35651755"],"doi":["10.3389/fcimb.2022.906563"]}}